AtaiBeckley Names Michael Faerm CFO as BPL-003 Advances Toward Phase 3
AtaiBeckley will appoint Michael Faerm as Chief Financial Officer effective March 9, 2026, with Anne Johnson shifting to Chief Accounting Officer to ensure continuity. Faerm’s 25+ years of life-science finance experience will guide capital markets activities as BPL-003 advances toward Phase 3.
1. CFO Appointment
AtaiBeckley will appoint Michael Faerm as Chief Financial Officer on March 9, 2026, while current CFO Anne Johnson transitions to Chief Accounting Officer to maintain continuity in accounting and financial operations.
2. Executive Background
Faerm brings over 25 years of finance experience in life sciences, including CFO roles at Viracta Therapeutics and Artiva Biotherapeutics, interim CFO at Harpoon Therapeutics where he led a $150 million financing, and equity research roles at Credit Suisse and Wells Fargo Securities.
3. Strategic Implications
As CFO, Faerm will oversee the company’s financial strategy and capital markets activities, supporting funding for late-stage development as BPL-003 moves toward Phase 3 and other clinical programs progress.